Clinical trials: Chronic Obstructive
Pulmonary Disease, Chronic Obstructive
A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COPD is a progressive disease characterized by increasing obstruction to airflow and the progressive development of respiratory symptoms including chronic cough, increased sputum production, dyspnea and wheezing.
- Trial name
- NCT03474081
- Testing
- FF/UMEC/VI, Tiotropium, Albuterol/salbutamol
- Where
- 72 sites in United States, Poland and 1 more
- Volunteers
- 800 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Predictive Ability of the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) for Acute Exacerbations (PACE) in Patients With COPD
Chronic Obstructive Pulmonary Disease (COPD) is a major health concern, with a substantial impact on a patient's life. However, the impact of COPD is currently under-recognised and, as a result, COPD is under-treated.
- Trial name
- PACE (NCT01254032)
- Where
- 19 sites in Australia, China and 2 more
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Insomnia
A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia
To evaluate the long-term safety and efficacy of eszopiclone administered for 12 weeks in elderly subjects with primary chronic insomnia.Administration of eszopiclone 2 mg daily at bedtime for 12 weeks in elderly subjects with a…
- Trial name
- NCT00386334
- Testing
- Eszopiclone
- Where
- 82 sites in United States
- Volunteers
- 388 people
- Sponsor
- Sumitomo Pharma America, Inc.
Pulmonary Disease, Chronic Obstructive
Effect of Spiriva on the Activities of Daily Living Score Recommended in Austrian COPD Guidelines
The primary goal of this post marketing surveillance (PMS) study is to document the efficacy of Tiotropium (Spiriva) to improve physical activity measured by a score that is recommended in national chronic obstructive pulmonary…
- Trial name
- NCT00615992
- Testing
- Tiotropium
- Where
- 73 sites in Austria
- Volunteers
- 754 people
- Sponsor
- Boehringer Ingelheim
COPD
Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®
A Randomized, Double-Blind, Parallel Group, 28-Week Chronic Dosing, Multi-Center Long-term Extension Study to Assess the Safety and Efficacy in Japanese Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease…
- Trial name
- NCT03262012
- Testing
- BGF MDI (PT010), GFF MDI (PT003), BFF MDI (PT009)
- Where
- 79 sites in Japan
- Volunteers
- 416 people
- Sponsor
- Pearl Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
Exacerbations Among Patients Receiving Breztri (EROS Study)
EROS was a retrospective analysis of people with COPD using the MORE2 Registry®. Inclusion required ≥1 severe, ≥2 moderate, or ≥1 moderate exacerbation while on other maintenance treatment.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Retrospective Studies
- Trial name
- NCT06514144
- Testing
- BGF
- Where
- United States
- Volunteers
- 2,409 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection
The aim of the study is to investigate whether the early introduction of maintenance bronchodilator therapy during an acute symptomatic episode of the disease shows benefits on the recovery of symptoms.
- Trial name
- NCT01483625
- Testing
- tiotropium
- Where
- 27 sites in United States
- Volunteers
- 140 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)
Patients with chronic obstructive pulmonary disease (COPD) have elevated risk of mortality and cardiopulmonary events, particularly following exacerbations.
- Trial name
- SKOPOS:MAZI (NCT06744374)
- Testing
- BGF, MITT
- Where
- United States
- Volunteers
- 22,369 people
- Sponsor
- AstraZeneca
COPD
Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD
The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product as measured by increases in FEV1.
- Trial name
- NCT03480997
- Testing
- Albuterol Sulfate and Ipratropium Bromide, Albuterol Sulfate
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Pneuma Respiratory, Inc
Pulmonary Disease, Chronic Obstructive
Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler.
GSK573719 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for the treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01521390
- Testing
- GSK573719 62.5 mcg (one strip), GSK573719 62.5 mcg(two strips), GSK573719 125 mcg (one strip)
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).
A 24 week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 18mcg of tiotropium inhalation capsules administered by Handihaler once daily plus Pro Re Nata (PRN) albuterol…
- Trial name
- NCT00523991
- Testing
- tiotropium
- Where
- 62 sites in United States, Belgium and 8 more
- Volunteers
- 457 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase IIa, open-label, repeat-dose trial to investigate the pharmacokinetics (PK), safety and tolerability of single and multiple twice daily doses of inhaled Aclidinium Bromide/Formoterol Fumarate 400/12 μg in 20 Chinese male…
- Trial name
- NCT03276078
- Testing
- Aclidinium Bromide/Formoterol Fumarate 400/12μg BID
- Where
- China
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow.
- Trial name
- NCT07355868
- Testing
- REGEND007
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Regend Therapeutics
COPD (Chronic Obstructive Pulmonary Disease)
A Phase 2 Trial of JKN24011 in COPD
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Subcutaneous JKN24011 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT07440524
- Testing
- JKN24011
- Where
- China
- Volunteers
- 215 people
- Sponsor
- Joincare Pharmaceutical Group Industry Co., Ltd
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Symptoms Over 24 Hours in Patients With Chronic Obstructive Pulmonary Disease - LASSYC Study
No previous studies have evaluated the frequency and severity of Chronic Obstructive Pulmonary Disease (COPD) symptoms over a period of 24 hours (early morning, daytime and nigth-time symptoms) in stable COPD patients seen in…
- Trial name
- LASSYC (NCT03381560)
- Where
- 8 sites in Brazil
- Volunteers
- 602 people
- Sponsor
- AstraZeneca
Opioid-Induced Constipation
Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The purpose of this study is to evaluate the long-term safety and tolerability of CB-5945 for the treatment of opioid-induced constipation (OIC) in adults taking opioid therapy for chronic non-cancer pain.
- Trial name
- NCT01696643
- Testing
- CB-5945
- Volunteers
- 1,407 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Pulmonary Disease, Chronic Obstructive
Safety, Blood Levels and Effects of GW642444
GW642444 (the study medicine) is a new experimental medicine for treating asthma and chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00469040
- Testing
- GW642444M for 14 days
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Graft-versus-host-disease
A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
This study will be conducted to evaluate the safety, efficacy, and pharmacokinetics of axatilimab monotherapy in Chinese participants with recurrent or refractory active chronic graft-versus-host disease after systemic therapy.
- Trial name
- NCT06843408
- Testing
- INCA034176
- Where
- 9 sites in China
- Volunteers
- 32 people
- Sponsor
- Incyte Corporation
Pulmonary Disease, Chronic Obstructive
Post-marketing Surveillance of Ventilat® Metered Dose Inhaler in Chronic Obstructive Bronchitis
Study to obtain further information on the tolerability and efficacy of Ventilat® metered-dose inhaler in the treatment of Chronic Obstructive bronchitis under conditions of daily practice
- Trial name
- NCT02233920
- Testing
- Ventilat® - metered dose inhaler
- Volunteers
- 716 people
- Sponsor
- Boehringer Ingelheim
Wounds
Trial of PICO Versus Standard Care in Chronic and Sub-acute Wounds
Randomised Controlled Trial of PICO (a portable Negative Pressure Wound Therapy) versus standard care in patients with chronic and sub-acute wounds.
- Trial name
- NCT02458859
- Testing
- PICO (single use portable negative pressure wound therapy)
- Where
- 20 sites in Canada, United Kingdom
- Volunteers
- 62 people
- Sponsor
- Smith & Nephew, Inc.